JP2024508922A - セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 - Google Patents
セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 Download PDFInfo
- Publication number
- JP2024508922A JP2024508922A JP2023553664A JP2023553664A JP2024508922A JP 2024508922 A JP2024508922 A JP 2024508922A JP 2023553664 A JP2023553664 A JP 2023553664A JP 2023553664 A JP2023553664 A JP 2023553664A JP 2024508922 A JP2024508922 A JP 2024508922A
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- atoms
- hydrogen
- optionally replaced
- available
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155634P | 2021-03-02 | 2021-03-02 | |
| US63/155,634 | 2021-03-02 | ||
| PCT/CA2022/050296 WO2022183288A1 (en) | 2021-03-02 | 2022-03-02 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024508922A true JP2024508922A (ja) | 2024-02-28 |
| JP2024508922A5 JP2024508922A5 (https=) | 2025-03-04 |
| JPWO2022183288A5 JPWO2022183288A5 (https=) | 2025-03-04 |
Family
ID=83153685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553664A Pending JP2024508922A (ja) | 2021-03-02 | 2022-03-02 | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 |
| JP2023553660A Pending JP2024508545A (ja) | 2021-03-02 | 2022-03-02 | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553660A Pending JP2024508545A (ja) | 2021-03-02 | 2022-03-02 | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240166630A1 (https=) |
| EP (2) | EP4301730A4 (https=) |
| JP (2) | JP2024508922A (https=) |
| KR (2) | KR20230154220A (https=) |
| CN (2) | CN117500788A (https=) |
| AU (2) | AU2022229037A1 (https=) |
| BR (1) | BR112023017754A2 (https=) |
| CA (2) | CA3210275A1 (https=) |
| IL (2) | IL305622A (https=) |
| MX (2) | MX2023010316A (https=) |
| WO (2) | WO2022183287A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| KR20250053871A (ko) * | 2022-08-31 | 2025-04-22 | 사이빈 아이알엘 리미티드 | 트립타민 화합물, 조성물, 및 사용 방법 |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| CN121752545A (zh) * | 2023-11-06 | 2026-03-27 | 宜昌人福药业有限责任公司 | 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途 |
| WO2025104490A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| WO2025104491A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05507288A (ja) * | 1990-10-15 | 1993-10-21 | フアイザー・インコーポレイテツド | インドール誘導体 |
| JPH08333363A (ja) * | 1995-06-06 | 1996-12-17 | Pfizer Inc | インドール誘導体 |
| US20090062367A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched eletriptan |
| WO2020181194A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| JP2023512821A (ja) * | 2020-02-04 | 2023-03-29 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
| JP2023513679A (ja) * | 2020-02-04 | 2023-04-03 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60222396T2 (de) * | 2001-03-29 | 2008-05-15 | Eli Lilly And Co., Indianapolis | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste |
| TWI318621B (en) * | 2006-08-03 | 2009-12-21 | Nat Bureau Of Controlled Drugs Dept Of Health | A series of deuterium labelled compounds as drug testing standards and their preparations |
| EP2753605B1 (en) * | 2011-09-09 | 2019-03-27 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| US20190358238A1 (en) * | 2016-11-16 | 2019-11-28 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| TW202144369A (zh) * | 2020-04-26 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 海鞘素類衍生物及其製備方法與醫藥用途 |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20240096817A (ko) * | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
-
2022
- 2022-03-02 AU AU2022229037A patent/AU2022229037A1/en active Pending
- 2022-03-02 IL IL305622A patent/IL305622A/en unknown
- 2022-03-02 CA CA3210275A patent/CA3210275A1/en active Pending
- 2022-03-02 EP EP22762289.1A patent/EP4301730A4/en active Pending
- 2022-03-02 JP JP2023553664A patent/JP2024508922A/ja active Pending
- 2022-03-02 KR KR1020237033368A patent/KR20230154220A/ko active Pending
- 2022-03-02 MX MX2023010316A patent/MX2023010316A/es unknown
- 2022-03-02 WO PCT/CA2022/050295 patent/WO2022183287A1/en not_active Ceased
- 2022-03-02 JP JP2023553660A patent/JP2024508545A/ja active Pending
- 2022-03-02 WO PCT/CA2022/050296 patent/WO2022183288A1/en not_active Ceased
- 2022-03-02 CN CN202280032370.6A patent/CN117500788A/zh active Pending
- 2022-03-02 AU AU2022229695A patent/AU2022229695A1/en active Pending
- 2022-03-02 US US18/279,293 patent/US20240166630A1/en active Pending
- 2022-03-02 KR KR1020237033351A patent/KR20230154219A/ko active Pending
- 2022-03-02 MX MX2023010317A patent/MX2023010317A/es unknown
- 2022-03-02 IL IL305481A patent/IL305481A/en unknown
- 2022-03-02 CN CN202280032373.XA patent/CN117242065A/zh active Pending
- 2022-03-02 CA CA3210270A patent/CA3210270A1/en active Pending
- 2022-03-02 BR BR112023017754A patent/BR112023017754A2/pt unknown
- 2022-03-02 US US18/279,290 patent/US20240166599A1/en active Pending
- 2022-03-02 EP EP22762290.9A patent/EP4301747A4/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05507288A (ja) * | 1990-10-15 | 1993-10-21 | フアイザー・インコーポレイテツド | インドール誘導体 |
| JPH08333363A (ja) * | 1995-06-06 | 1996-12-17 | Pfizer Inc | インドール誘導体 |
| US20090062367A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched eletriptan |
| WO2020181194A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| JP2023512821A (ja) * | 2020-02-04 | 2023-03-29 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
| JP2023513679A (ja) * | 2020-02-04 | 2023-04-03 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024508545A (ja) | 2024-02-27 |
| KR20230154219A (ko) | 2023-11-07 |
| AU2022229037A1 (en) | 2023-09-28 |
| CA3210270A1 (en) | 2022-09-09 |
| IL305622A (en) | 2023-11-01 |
| EP4301730A1 (en) | 2024-01-10 |
| KR20230154220A (ko) | 2023-11-07 |
| EP4301747A4 (en) | 2025-01-22 |
| CN117242065A (zh) | 2023-12-15 |
| EP4301747A1 (en) | 2024-01-10 |
| IL305481A (en) | 2023-10-01 |
| EP4301730A4 (en) | 2025-01-22 |
| BR112023017754A2 (pt) | 2023-11-21 |
| WO2022183287A1 (en) | 2022-09-09 |
| WO2022183288A1 (en) | 2022-09-09 |
| MX2023010317A (es) | 2023-11-09 |
| AU2022229695A1 (en) | 2023-09-28 |
| CA3210275A1 (en) | 2022-09-09 |
| CN117500788A (zh) | 2024-02-02 |
| US20240166599A1 (en) | 2024-05-23 |
| MX2023010316A (es) | 2023-11-09 |
| US20240166630A1 (en) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026010068A (ja) | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 | |
| JP7824222B2 (ja) | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 | |
| JP2024508922A (ja) | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 | |
| JP2023553094A (ja) | 中枢神経系障害の治療のためのセロトニン作動性薬としての３位環－アミンインドール誘導体 | |
| AU2022328466A1 (en) | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto | |
| JP2025529948A (ja) | セロトニンに関する障害の治療に有用なセロトニン作動薬としてのインドリン誘導体 | |
| HK40105243A (zh) | 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物 | |
| HK40106138A (zh) | 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物 | |
| HK40083780A (en) | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders | |
| HK40084439A (en) | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders | |
| HK40083776A (en) | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250221 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251120 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260302 |